1. AD is a chronic, relapsing, and remitting inflammatory skin disease associated with significant reduction in quality of life. Consensus: 100% (Voting Result*: 9, 8, 0, 0, 0) *Voting results reflect number of authors voting strongly agree, agree, neither agree nor disagree, disagree, or strongly disagree, respectively.
This panel agreed on the importance of highlighting the chronic inflammatory nature of AD, despite the often episodic presentation, as a counselling point for patients seeking Voting results reflect number of authors voting strongly agree, agree, neither agree nor disagree, disagree, or strongly disagree, respectively. management of their disease. In addition, the significant impact on quality of life and daily activities was seen as important in highlighting the need to improved care and management.
Patients should understand that their disease is caused by aberrant inflammation and should be advised of the ongoing need for therapy, including maintenance therapy, in minimizing disease activity and preventing flares. There are many overlapping factors contributing to the pathophysiology of AD in adults. While no one genetic or environmental trigger is responsible for development of disease in an individual, it is important to communicate the overarching role of immune dysregulation and skin barrier dysfunction affecting disease pathogenesis at multiple stages along the pathway.
The pathophysiology of AD is
Patient counselling should highlight the importance of minimizing skin inflammation and maintaining or restoring skin barrier function to positively affect the skin microbiome, reduce the effect of environmental or allergic triggers on the skin, and reduce pruritus, which may further exacerbate disease. No single assessment tool sufficiently captures the overall severity and impact of AD, and there is significant variability with respect to the validity and clinical utility of the available assessment tools. PGA and BSA effectively capture the primary objective measures of disease impact: lesion severity and extent.
Assessment

Eczema Area and Severity Index (EASI) and
In addition, clinical judgement is necessary to form an overall assessment of disease severity. Importantly, disease recurrence, flares, and persistence are important considerations in the overall impact of disease on patients with AD. In addition, involvement of functionally important or highly visible areas, including face, hands, or genitals, significantly affects quality of life and daily activities. All patients should be assessed, whether formally or informally, for pruritus and sleep disturbance, as these are important quality-of-life indicators not captured by objective assessments. POEM is the best-validated formal assessment of patient-reported outcomes, can be easily implemented in clinic, and captures both of these important quality-of-life measures. As an alternative, DLQI and/or pruritus NRS are practical for clinical use, but it should be noted that neither captures sleep as an outcome measure.
Comorbidities
Atopic comorbidities include asthma, allergic
rhinitis, food allergy, and ocular disorders. Depression and anxiety are also more prevalent in patients with AD. Health care providers should be aware of these comorbidities and refer appropriately. The panel agreed that given the complex pathophysiology of disease and impact on patient quality of life, therapies should be aimed at improving the disease characteristics listed above. This includes basic care such as emollients, skin hydration with baths, and irritant avoidance, as well as both broad and targeted therapies.
7. Moisturizers, topical corticosteroids, and topical calcineurin inhibitors have been shown to significantly reduce signs and symptoms of AD and are first-line therapy. Consensus: 100% (Voting Result*: 11, 6, 0, 0, 0) *Voting results reflect number of authors voting strongly agree, agree, neither agree nor disagree, disagree, or strongly disagree, respectively.
Patients should be counselled that, due to the chronic nature of their disease, ongoing basic care, including moisturizers, is important for disease control and prevention of flares even in the absence of active disease.
Topical corticosteroids (TCS) should be used first line and medication choice should consider potency, formulation, patient age, and treatment area, with avoidance of potent TCS on areas such as the face, neck, skin folds, or genitals.
Topical calcineurin inhibitors (TCI) should be used in patients with inadequate response to TCS and in those with frequent disease relapse. Patients should be counselled that despite the black box warning, the risk of lymphoma associated with TCI use is not supported by clinical data.
The phosphodiesterase E4 inhibitor crisaborole has recently been approved in some countries for the treatment of AD and can also be used to control the disease. Systemic therapies should be considered for patients who fail first-line topical therapies or for whom first-line therapies are not appropriate. Treatment failure may be considered as inadequate response after 8 weeks of at least moderate-potency topical therapy (TCS/TCI) or disease flare within 1 week of treatment discontinuation. In many countries, dupilumab is currently the only systemic therapy indicated for the long-term treatment of AD, as other therapies are limited by toxicity. When indicated and approved therapies are not accessible or appropriate, conventional systemic therapies may be considered for specific patient groups. Amongst the off-label systemic immunosuppressants used to treat moderate-tosevere AD, MTX may be considered first-line for stable disease due to its safety and low cost. CsA may also be considered for rapid control but should not be used as a long-term therapy. CsA is approved for AD in some countries. Laboratory monitoring for these agents should be noted and assessed as required.
Ultraviolet B (UVB
When medications indicated
11. Consider systemic corticosteroids only in short courses as rescue therapy.
Consensus: 100% (Voting Result*: 4, 13, 0, 0, 0) *Voting results reflect number of authors voting strongly agree, agree, neither agree nor disagree, disagree, or strongly disagree, respectively.
The use of systemic corticosteroids should be avoided in patients with AD. Systemic corticosteroids should be reserved for unusual circumstances such as severe flares before the introduction of another systemic therapy and should only be administered in short courses due to concerns with toxicity and long-term side effects. These medications should be tapered slowly so as to minimize disease flare upon discontinuation of therapy.
